Résumés
Résumé
L’ingestion de nourriture déclenche une réponse hormonale complexe, dont le but est notamment de minimiser les oscillations de la glycémie grâce à une stimulation appropriée du captage de glucose par le foie et les tissus musculaire et adipeux. L’activité insulinosécrétoire des cellules β du pancréas joue un rôle majeur dans cette réponse. Bien que l’augmentation du glucose sanguin soit le stimulus principal de l’insulinosécrétion, des hormones intestinales, libérées par des cellules endocrines de l’épithélium intestinal lors du passage de nutriments, jouent un rôle important de potentialisation de l’effet du glucose sur les cellules β pancréatiques. Ces hormones, appelées gluco-incrétines, sont principalement le GLP-1 (glucagon like peptide-1) et le GIP (glucose-dependent insulinotropic polypeptide). Elles agissent au niveau des cellules β pancréatiques en se liant à des récepteurs heptahélicaux couplés à l’activation de l’adénylate-cyclase. Outre leur capacité de potentialiser la sécrétion d’insuline induite par le glucose, ces hormones stimulent également la production d’insuline par des effets transcriptionnels et post-transcriptionnels, et ont également un effet positif sur le contrôle de la masse cellulaire β. L’activité insulinotrope, dépendante du glucose, du GLP-1 étant préservée au cours du diabète de type 2, ce peptide est considéré comme un médicament potentiel pour le traitement de cette maladie.
Summary
Nutrient ingestion triggers a complex hormonal response aimed at stimulating glucose utilization in liver, muscle and adipose tissue to minimize the raise in blood glucose levels. Insulin secretion by pancreatic β cells plays a major role in this response. Although the β cell secretory response is mainly controlled by blood glucose levels, gut hormones secreted in response to food intake have an important role in potentiating glucose-stimulated insulin secretion. These gluco-incretin hormones are GLP-1 (glucagon-like peptide-1) and GIP (gluco-dependent insulinotropic polypeptide). Their action on pancreatic β cells depends on binding to specific G-coupled receptors linked to activation of the adenylyl cyclase pathway. In addition to their effect on insulin secretion both hormones also stimulate insulin production at the transcriptional and translational level and positively regulate β cell mass. Because the glucose-dependent insulinotropic action of GLP-1 is preserved in type 2 diabetic patients, this peptide is now developed as a novel therapeutic drug for this disease.
Parties annexes
Références
- 1. Ørskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-11.
- 2. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993; 133: 2861-70.
- 3. Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide I. Proc Natl Acad Sci USA 1992; 89: 8641-5.
- 4. Weir GC, Mojsov S, Hendrick GK, Habener JF. Glucagon-like peptide 1 (7-37) actions on endocrine pancreas. Diabetes 1989; 38: 338-42.
- 5. Ozaki N, Shibasaki T, Kashima Y, et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2: 805-11.
- 6. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-6.
- 7. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 2002; 51: 1443-52.
- 8. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-8.
- 9. Ehses JA, Pelech SL, Pederson RA, McIntosh CHS. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J Biol Chem 2002; 277: 37088-97.
- 10. Gomez E, Pritchard C, Herbert TP. cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic β-cells. J Biol Chem 2002; 277: 48146-51.
- 11. Schjoldager BTG, Mortensen PE, Christiansen J, Ørskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 1989; 3: 703-8.
- 12. Wettergren A, Vojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984-92.
- 13. Turton MD, O’SHea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72.
- 14. Szayna M, Doyle ME, Betkey JA, et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000; 141: 1936-41.
- 15. Larsen PJ, Tang-Christansen M, Holst JJ, Ørskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997; 77: 257-70.
- 16. Burcelin R, Dolci W, Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent. In vivo analysis in GLUT2-null mice. Diabetes 2000; 49: 1643-8.
- 17. Burcelin R, DaCosta A, Drucker D, Thorens B. Glucose competence of the hepatoporal vein sensor requires the presence of an activated GLP-1 receptor. Diabetes 2001; 50: 1720-8.
- 18. Scrocchi LA, Brown TJ, MacLusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide-1 receptor gene. Nat Med 1996; 2: 1254-8.
- 19. Miyawaki K, Yamada Y, Yano H, et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 14843-7.
- 20. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-42.
- 21. Rachman J, Gribble FM, Barrows BE, Levy JC, Buchanan KD, Turner RC. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 1996; 45: 1524-30.
- 22. Rachman J, Barrows BA, Levy JC, Turner RC. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjets with NIDDM. Diabetologia 1997; 40: 205-11.
- 23. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-30.
- 24. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18: 430-41.